University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England : a review comparing the assessment by HAS and NICE

Simple item page
dc.contributor.authorArmoiry, Xavier
dc.contributor.authorSpäth, Hans-Martin
dc.contributor.authorHenaine , Anna-Maria
dc.contributor.authorDussart, Claude
dc.contributor.authorCounsell, Carl
dc.contributor.authorConnock, Martin
dc.contributor.institutionUniversity of Aberdeen.Grampian Data Safe Haven (DaSH)en
dc.contributor.institutionUniversity of Aberdeen.Chronic Disease Research Groupen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.date.accessioned2021-12-24T00:07:09Z
dc.date.available2021-12-24T00:07:09Z
dc.date.embargoedUntil2021-12-24
dc.date.issued2021-06-03
dc.description.statusPeer revieweden
dc.format.extent7
dc.format.extent236337
dc.identifier183993945
dc.identifier8d9976c8-407f-4c0a-9e7f-df4fa8e21e6e
dc.identifier85098540547
dc.identifier.citationArmoiry, X, Späth, H-M, Henaine , A-M, Dussart, C, Counsell, C & Connock, M 2021, 'Ocrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England : a review comparing the assessment by HAS and NICE', Expert opinion on biological therapy, vol. 21, no. 6, pp. 741-747. https://doi.org/10.1080/14712598.2021.1865305en
dc.identifier.doi10.1080/14712598.2021.1865305
dc.identifier.iss6en
dc.identifier.issn1744-7682
dc.identifier.otherJisc: fa87f0d62ae5462cbdd3e23ad77c1218
dc.identifier.otherORCID: /0000-0001-6622-7839/work/164505653
dc.identifier.urihttps://hdl.handle.net/2164/17774
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85098540547&partnerID=8YFLogxKen
dc.identifier.vol21en
dc.language.isoeng
dc.relation.ispartofExpert opinion on biological therapyen
dc.subjectprimary progressive multiple sclerosisen
dc.subjectOcrelizumaben
dc.subjectNICEen
dc.subjectHASen
dc.subjectHealth technology assessmenten
dc.subjectEnglanden
dc.subjectFranceen
dc.subjecthealth technology assessmenten
dc.subjectenglanden
dc.subjectocrelizumaben
dc.subjectfranceen
dc.subjecthasen
dc.subjectR Medicineen
dc.subjectDrug Discoveryen
dc.subjectClinical Biochemistryen
dc.subjectPharmacologyen
dc.subject.lccRen
dc.titleOcrelizumab not recommended in France for patients with primary progressive multiple sclerosis while recommended in England : a review comparing the assessment by HAS and NICEen
dc.typeJournal itemen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Armoiry_etal_EOBT_Ocrelizumab_AAM.pdf
Size:
230.8 KB
Format:
Adobe Portable Document Format
Download

Collections

All research

The Sir Duncan Rice Library

University of Aberdeen

Bedford Road

Aberdeen

AB24 3AA


Tel: +44 (0)1224 273330

Email: library@abdn.ac.uk

Share and keep up to date


FacebookTwitterWordpress